Add
UTHR to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| UTHR > SEC Filings for UTHR > Form 8-K on 26-May-2009 | All Recent SEC Filings |
26-May-2009
Regulation FD Disclosure
On May 26, 2009, United Therapeutics Corporation (the "Company") issued a press release regarding the approval by the United States Food and Drug Administration of ADCIRCA™ (tadalafil) tablets for oral administration, with a recommended dose of 40 mg, the first once-daily phosphodiesterase type 5 (PDE5) inhibitor for the treatment of pulmonary arterial hypertension. A copy of the press release is attached hereto as Exhibit 99.1.
The information contained in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Exhibits
(d) Exhibits
Exhibit No. Description of Exhibit
99.1 Press release dated May 26, 2009
|
|